- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06526195
심부전이 진행된 환자의 기계적 순환 지원의 안전성과 유효성을 평가하기 위한 시험 (TEAM-HF)
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
연구 개요
상태
상세 설명
Patients with heart failure (HF) suffer from a high degree of morbidity and mortality. Left ventricular assist device (LVAD) therapy has become the standard of care for the treatment of advanced HF patients who are deemed to be dependent on continuous intravenous inotropes, extending life expectancy, enhancing overall quality of life, and improving functional capacity. However, use of LVADs in ambulatory, non-inotrope dependent advanced HF population is limited. Elevated mean pulmonary artery pressure (PAP) secondary to left ventricular failure has emerged as a potential predictor of increased mortality risk for patients refractory to maximally tolerated guideline directed medical therapy (GDMT). In these patients, left ventricular failure with elevated mean PAP may represent objective criteria to identify advanced HF patients requiring heart replacement therapies such as LVAD.
The TEAM-HF IDE trial will enroll approximately 850 subjects with New York Heart Association (NYHA) Class IIIB/IV HF who had a prior heart failure hospitalization and an elevated mean PAP secondary to left ventricular failure. Elevated mean PAP will be identified using an implanted PAP monitoring sensor, the CardioMEMS PA Sensor. All subjects enrolled can have a previously implanted CardioMEMS PA Sensor or, if not, will be implanted with the CardioMEMS PA Sensor after enrollment. The overall objectives of TEAM-HF trial are two-fold: 1) To determine whether PAP can objectively identify patients most at risk for worsening HF and therefore most likely to benefit from earlier intervention with LVAD therapy and 2) To determine the benefit of LVAD therapy in non-inotrope advanced HF patients with elevated mean PAP refractory to GDMT.
The trial will include approximately 75 global sites and consists of a Randomized Arm and a Single Arm Registry.
The TEAM-HF Randomized Arm is a prospective, randomized, open-label study of the HeartMate 3 (HM3) left ventricular assist system (LVAS) versus continued GDMT in non-inotrope dependent HF patients. The objectives of the Randomized Arm are 1) To establish an objective disease-state criteria to trigger referral for a HM3 LVAS and 2) Demonstrate improvement in survival when non-inotrope dependent advanced HF patients are treated with the HM3 LVAS compared to being managed on medical therapy alone.
The TEAM-HF Single Arm Registry is a prospective, single-arm, open-label study of non-inotrope dependent HF patients who do not meet a mean PAP threshold after GDMT optimization. The objective of the Single Arm Registry is to characterize the progression of patients with non-inotrope dependent HF without elevated PAP.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Nourdine Chakouri, PhD
- 전화번호: 925-989-5982
- 이메일: nourdine.chakouri@abbott.com
연구 장소
-
-
Holland
-
Rotterdam, Holland, 네덜란드, 3015 CE
- 모병
- Erasmus MC - Thoraxcenter
-
연락하다:
- Nico Van Den Berg
- 전화번호: +31-010-703-9307
- 이메일: n.berg@erasmusmc.nl
-
수석 연구원:
- Rudolf De Boer, MD
-
-
Utrecht
-
Utrecht, Utrecht, 네덜란드, 3584 CX
- 모병
- UMC Utrecht
-
수석 연구원:
- Linda Van Laake, MD
-
연락하다:
- Manon Kuikhoven
- 전화번호: (088) 755-9432
- 이메일: m.j.kuikhoven@umcutrecht.nl
-
-
-
-
Copenhagen
-
Copenhagen, Copenhagen, 덴마크, 2100
- 모병
- Rigshospitalet
-
연락하다:
- Christina Moeller
- 전화번호: +00 453 545 6757
- 이메일: Christina.Moeller@regionh.dk
-
수석 연구원:
- Kasper Rossing, MD
-
-
-
-
Saxon
-
Hanover, Saxon, 독일, 30625
- 모병
- Medizinische Hochschule Hannover
-
수석 연구원:
- Dominik Berliner, MD
-
연락하다:
- Antje Juergens
- 전화번호: +49-0115-323-1113
- 이메일: juergens.antje@mh-hannover.de
-
-
Saxony
-
Leipzig, Saxony, 독일, 04289
- 모병
- Herzzentrum Leipzig GmbH
-
수석 연구원:
- Michael Borger, MD
-
연락하다:
- Victoria Himstedt
- 전화번호: +49 341 865 25
- 이메일: victoria.himstedt@helios-health-institute.com
-
-
State of Berlin
-
Berlin, State of Berlin, 독일, 13353
- 모병
- Deutsches Herzzentrum der Charité
-
수석 연구원:
- Felix Schoenrath, MD
-
연락하다:
- Annegret Schneider
- 전화번호: +49-304-593-2303
- 이메일: schneider@dhzb.de
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85006
- 빼는
- Banner-University Medical Center Phoenix
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- 모병
- Baptist Health Medical Center
-
수석 연구원:
- Patrick Campbell, MD
-
연락하다:
- Victoria Marren
- 전화번호: 678-654-0327
- 이메일: victoria.marren@baptist-health.org
-
-
California
-
Sacramento, California, 미국, 95816
- 모병
- Sutter Medical Center
-
연락하다:
- Jessica Mccall
- 전화번호: 916-887-4654
- 이메일: jessica.mccall@sutterhealth.org
-
수석 연구원:
- Michael Gibson, MD
-
San Francisco, California, 미국, 94143
- 모병
- University of California at San Francisco
-
연락하다:
- Tyre Richardson
- 전화번호: (209) 650-5302
- 이메일: tyre.richardson@ucsf.edu
-
수석 연구원:
- Shweta Motiwala, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Washington Hospital Center
-
수석 연구원:
- Sheikh Farooq, MD
-
연락하다:
- Hellina Birru
- 전화번호: 202-877-6334
- 이메일: hellina.t.birru@medstar.net
-
-
Florida
-
Gainesville, Florida, 미국, 32610
- 모병
- Shands at the University of Florida
-
수석 연구원:
- Mustafa Ahmed, MD
-
연락하다:
- Erikson Walter
- 전화번호: 269-331-9581
- 이메일: erikson.walter@ufl.edu
-
Weston, Florida, 미국, 33331
- 모병
- Cleveland Clinic Florida
-
연락하다:
- Maria Mejia-Gomez
- 전화번호: 954-659-5888
- 이메일: mejiagm@ccf.org
-
수석 연구원:
- Mauricio Velez, MD
-
-
Georgia
-
Atlanta, Georgia, 미국, 30309
- 모병
- Piedmont Heart Institute
-
수석 연구원:
- Catherine Marti, MD
-
연락하다:
- Andrew Bailey
- 전화번호: 404-605-4098
- 이메일: Andrew.Bailey1@piedmont.org
-
Augusta, Georgia, 미국, 30901
- 모병
- Piedmont Augusta Hospital
-
수석 연구원:
- Darshak Karia, MD
-
연락하다:
- Jennifer Hansen
- 전화번호: 706-724-2463
- 이메일: jennifer.hansen@piedmont.org
-
Marietta, Georgia, 미국, 30060
- 모병
- WellStar Kennestone Hospital
-
수석 연구원:
- Abdul Bikak, MD
-
연락하다:
- Amuthanayaki Kanagaraj
- 전화번호: 470-793-7554
- 이메일: amuthanayaki.kanagaraj2@wellstar.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago
-
연락하다:
- Kristen Hanauer
- 전화번호: 773-702-8716
- 이메일: kristen.hanauer@bsd.uchicago.edu
-
수석 연구원:
- Nikhil Narang, MD
-
Oakbrook Terrace, Illinois, 미국, 60181
- 모병
- Advocate Health & Hospitals Corporation
-
연락하다:
- Mairead Delaney
- 전화번호: 708-684-4209
- 이메일: mairead.delaney@aah.org
-
수석 연구원:
- Vinh Chau, MD
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46240
- 모병
- St. Vincent Hospital
-
수석 연구원:
- Ashwin Ravichandran, MD
-
연락하다:
- Regina Margiotti
- 전화번호: 317-338-6151
- 이메일: Regina.Margiotti@ascension.org
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa Hospitals & Clinics
-
연락하다:
- Page Scovel
- 전화번호: 319- 356-2585
- 이메일: Page-scovel@uiowa.edu
-
수석 연구원:
- Anthony Panos, MD
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- Kansas University Medical Center
-
연락하다:
- Terry Christenson
- 전화번호: 515-210-2626
- 이메일: tchristenson3@kumc.edu
-
수석 연구원:
- Zubair Shah, MD
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 종료됨
- University of Kentucky
-
Louisville, Kentucky, 미국, 40202
- 모병
- Norton Hospital
-
연락하다:
- Laurie Michelle Jones
- 전화번호: 502-891-8699
- 이메일: laurie.jones@nortonhealthcare.org
-
수석 연구원:
- Alkhalil Bassel, MD
-
-
Maine
-
Portland, Maine, 미국, 04102
- 모병
- Maine Medical Center
-
연락하다:
- Monica Palmeri
- 전화번호: 207-662-2090
- 이메일: monica.palmeri@mainehealth.org
-
수석 연구원:
- Peter Kennel, MD
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital
-
연락하다:
- Bronwen Rees-Weidemann
- 전화번호: 617-726-5508
- 이메일: brees-wiedemann@mgh.harvard.edu
-
수석 연구원:
- Erin Coglianese, MD
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- 모병
- Henry Ford Hospital
-
연락하다:
- Zack Malouf
- 전화번호: 313-585-7068
- 이메일: zmalouf1@hfhs.org
-
수석 연구원:
- Lindsey Aurora, MD
-
Grand Rapids, Michigan, 미국, 49503
- 모병
- Spectrum Health Butterworth Hospital
-
연락하다:
- Stephanie Hanson
- 전화번호: 616-391-0284
- 이메일: stephanie.hanson@corewellhealth.org
-
수석 연구원:
- Matthew Gonzalez, MD
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55407
- 모병
- Minneapolis Heart Institute
-
수석 연구원:
- Mosi Bennett, MD
-
연락하다:
- Kate Jappe
- 전화번호: 612-863-7347
- 이메일: Kate.Jappe@allina.com
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic
-
연락하다:
- Colleen Irlbeck
- 전화번호: 507-266-6879
- 이메일: Irlbeck.Colleen@mayo.edu
-
수석 연구원:
- Andrew Rosenbaum, MD
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- 모병
- St. Luke's Hospital
-
수석 연구원:
- Timothy Fendler, MD
-
연락하다:
- Amanda Huffman
- 전화번호: 816-932-0391
- 이메일: ahuffman@saint-lukes.org
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198
- 모병
- University of Nebraska Medical Center
-
연락하다:
- Ryan Ruskamp
- 전화번호: 402-836-9779
- 이메일: ryan.ruskamp@unmc.edu
-
수석 연구원:
- Adam Burdorf, DO
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모병
- Hackensack University Medical Center
-
수석 연구원:
- Kanika Mody, MD
-
연락하다:
- Manuel Castillo
- 전화번호: 551-996-2136
- 이메일: Manuel.Castillo@hmhn.org
-
Newark, New Jersey, 미국, 07112
- 모병
- Newark Beth Israel Medical Center
-
수석 연구원:
- Igor Gosev, MD
-
연락하다:
- Patel Bhargavi
- 전화번호: 516-600-1487
- 이메일: bhargavi.patel2@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87102
- 모병
- New Mexico Heart Institute
-
연락하다:
- Rebecca Jones
- 전화번호: 505-843-2827
- 이메일: Rebecca.Jones@lovelace.com
-
수석 연구원:
- Dana Booth, MD
-
-
New York
-
Manhasset, New York, 미국, 11030
- 모병
- North Shore University Hospital
-
연락하다:
- Salome Reddy
- 전화번호: 516-600-1459
- 이메일: seliareddy@northwell.edu
-
수석 연구원:
- Maria Avila, MD
-
New York, New York, 미국, 10032
- 모병
- New York-Presbyterian/Columbia University Medical Center
-
연락하다:
- Jessica Idumonyi
- 전화번호: 212-305-1368
- 이메일: joi2102@cumc.columbia.edu
-
수석 연구원:
- Dor Lotan, MD
-
Rochester, New York, 미국, 14642
- 모병
- University of Rochester Medical Center
-
연락하다:
- Lori Caufield
- 전화번호: (585) 273-4956
- 이메일: lori_caufield@urmc.rochester.edu
-
수석 연구원:
- Leway Chen, MD
-
The Bronx, New York, 미국, 10467
- 모병
- Montefiore Medical Center - Moses Campus
-
수석 연구원:
- Yogita Rochlani, MD
-
연락하다:
- Sabrina Sicilia
- 이메일: ssicilia@montefiore.org
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- University of North Carolina at Chapel Hill
-
연락하다:
- Hanna Mixon
- 전화번호: (919) 962-4896
- 이메일: hanna_mixon@med.unc.edu
-
수석 연구원:
- William Mostertz, MD
-
Charlotte, North Carolina, 미국, 28203
- 모병
- Carolinas Medical Center
-
연락하다:
- Dana Amaro
- 전화번호: 704-355-4794
- 이메일: dana.amaro@atriumhealth.org
-
수석 연구원:
- Joseph Mishkin, MD
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- 모병
- Christ Hospital
-
연락하다:
- Susanne Pasley
- 전화번호: 513-585-1777
- 이메일: susanne.pasley@thechristhospital.com
-
수석 연구원:
- Emani Sitaramesh, MD
-
Cleveland, Ohio, 미국, 44195
- 모병
- The Cleveland Clinic Foundation
-
연락하다:
- Barbara Gus
- 전화번호: 216-445-6552
- 이메일: gusb@ccf.org
-
수석 연구원:
- Michael Tong, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73112
- 모병
- Integris Baptist Medical Center
-
연락하다:
- Jill Bethany Fife
- 전화번호: (405) 951-8607
- 이메일: bethany.fife@integrishealth.org
-
수석 연구원:
- Luke Cunningham, MD
-
Tulsa, Oklahoma, 미국, 74104
- 모병
- Oklahoma Heart Institute at Utica
-
연락하다:
- Allyson O'Guin
- 전화번호: (918) 574-9253
- 이메일: allyson.oguin@hillcrest.com
-
수석 연구원:
- Luis David Meggo Quiroz, MD
-
Tulsa, Oklahoma, 미국, 74136
- 모병
- Saint Francis Hospital
-
수석 연구원:
- Douglas Ensley, MD
-
연락하다:
- Riley Pritzlaff
- 전화번호: 918-494-8500
- 이메일: rpritzlaff@saintfrancis.com
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 모병
- Oregon Health & Science University
-
수석 연구원:
- Johannes Steiner, MD
-
연락하다:
- Ricardo Mendoza
- 전화번호: (503) 494-9511
- 이메일: Mendozri@ohsu.edu
-
-
Pennsylvania
-
Abington, Pennsylvania, 미국, 19001
- 모병
- Abington Memorial Hospital
-
연락하다:
- Colleen Marchand
- 전화번호: 215-481-4661
- 이메일: colleen.marchand@jefferson.edu
-
수석 연구원:
- Alexander Shpilman, MD
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Penn State Milton S. Hershey Medical Center
-
수석 연구원:
- John Boehmer, MD
-
연락하다:
- Amanda Donnangelo
- 전화번호: 717-531-0850
- 이메일: adonnangelo@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- University of Pennsylvania
-
연락하다:
- Emma Markley
- 전화번호: 585-273-3760
- 이메일: Emma.markley@pennmedicine.upenn.edu
-
수석 연구원:
- Himabindu Vidula, MD
-
Philadelphia, Pennsylvania, 미국, 15213
- 모병
- University of Pittsburgh Medical Center (UPMC)
-
수석 연구원:
- Gavin Hickey, MD
-
연락하다:
- Abbey Sung
- 전화번호: 412-648-6024
- 이메일: sunga3@upmc.edu
-
Pittsburgh, Pennsylvania, 미국, 15212
- 모병
- Allegheny General Hospital
-
수석 연구원:
- Matthew Lander, MD
-
연락하다:
- Laurie Machen
- 전화번호: 412-359-6181
- 이메일: Laurie.MACHEN@ahn.org
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina
-
수석 연구원:
- Arman Kilic, MD
-
연락하다:
- Melissa Lamicq
- 전화번호: 954-683-4648
- 이메일: Lamicq@musc.edu
-
Columbia, South Carolina, 미국, 29203
- 모병
- Prisma Health Midlands
-
연락하다:
- Brooks Ferguson
- 전화번호: 843-442-0994
- 이메일: Brooks.Ferguson@prismahealth.org
-
수석 연구원:
- James Ampadu, MD
-
연락하다:
- Abigail Anderson
- 전화번호: 864-455-7629
- 이메일: Abigail.Anderson@prismahealth.org
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38120
- 모병
- The Stern Cardiovascular Foundation
-
연락하다:
- Rishi Bhula
- 전화번호: 901-271-2220
- 이메일: rishi.bhula@sterncardio.com
-
수석 연구원:
- Todd Edwards, MD
-
-
Texas
-
Austin, Texas, 미국, 78705
- 모병
- Ascension Texas Cardiovascular
-
연락하다:
- Jennifer Mcsorley
- 전화번호: 702-427-2014
- 이메일: jennifer.mcsorley@ascension.org
-
수석 연구원:
- Raymond Bietry, MD
-
Dallas, Texas, 미국, 75246
- 모병
- Baylor University Hospital
-
연락하다:
- Shelby Shull
- 전화번호: 214-818-2587
- 이메일: Shelby.Shull@BSWHealth.org
-
수석 연구원:
- Cesar Guerrero-Miranda, MD
-
Houston, Texas, 미국, 77030
- 모병
- Houston Methodist
-
연락하다:
- Mary Kelly
- 전화번호: (346) 238-8240
- 이메일: makelly@houstonmethodist.org
-
수석 연구원:
- Cindy Martin, MD
-
Houston, Texas, 미국, 77030
- 모병
- CHI St. Luke's Health Baylor College of Medicine Medical Center
-
수석 연구원:
- Ajith Nair, MD
-
연락하다:
- Wajeeha Abrar
- 전화번호: (713) 798-5404
- 이메일: Wajeeha.Abrar@bcm.edu
-
Houston, Texas, 미국, 77030
- 모병
- UTHealth Memorial Hermann
-
연락하다:
- Lawana Self
- 전화번호: 713-486-6751
- 이메일: lawana.self@uth.tmc.edu
-
수석 연구원:
- Nathan Sriram, MD
-
Plano, Texas, 미국, 75093
- 모병
- The Heart Hospital Baylor Plano
-
연락하다:
- Shelby McCoy
- 전화번호: 469-814-3524
- 이메일: shelby.mccoy@bswhealth.org
-
수석 연구원:
- Aasim Afzal, MD
-
Temple, Texas, 미국, 76508
- 모병
- Scott & White Memorial Hospital
-
연락하다:
- Rohini Bagewadi
- 전화번호: 254-724-1083
- 이메일: rohini.bagewadi@bswhealth.org
-
수석 연구원:
- Yevgeniy Khariton, MD
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
- 모병
- University of Utah Hospital
-
수석 연구원:
- Craig Selzman, MD
-
연락하다:
- Ashley Elmer
- 전화번호: 801-585-6775
- 이메일: ashley.elmer@hsc.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- 모병
- University of Virginia Medical Center
-
연락하다:
- Tevin Jefferson
- 전화번호: 434-982-1058
- 이메일: MFU3QX@uvahealth.org
-
수석 연구원:
- Mirnela Byku, MD
-
Richmond, Virginia, 미국, 23219
- 모병
- Virginia Commonwealth University
-
수석 연구원:
- Keyur Shah, MD
-
연락하다:
- Saige Dagenhart
- 전화번호: 402-677-0237
- 이메일: Saige.Dagenhart@vcuhealth.org
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53215
- 모병
- Aurora Medical Group
-
수석 연구원:
- Nasir Sulemanjee, MD
-
연락하다:
- Don Lobacz
- 전화번호: 414-649-3438
- 이메일: donald.lobacz@aah.org
-
-
-
-
Riyadh Region
-
Riyadh, Riyadh Region, 사우디 아라비아, 11525
- 모병
- King Fahad Medical City
-
수석 연구원:
- Mohammed Alreshidan, MD
-
연락하다:
- Joud Hewaidi
- 전화번호: +966-530003751
- 이메일: jhewaidi@kfmc.med.sa
-
Riyadh, Riyadh Region, 사우디 아라비아, 12713
- 모병
- King Faisal Specialist Hospital
-
연락하다:
- Luluah Altukhaifi
- 전화번호: +966 0556481098
- 이메일: laltukaifi@kfshrc.edu.sa
-
수석 연구원:
- Jehad Abdulhamid Al Buraiki, MD
-
-
-
-
State of Vienna
-
Vienna, State of Vienna, 오스트리아, 1090
- 모병
- AKH -Wien
-
연락하다:
- Julia Riebandt, MD, PhD
- 전화번호: +43 1 40400-69660
- 이메일: julia.riebandt@meduniwien.ac.at
-
수석 연구원:
- Daniel Zimpfer, MD
-
-
-
-
Piedmont
-
Turin, Piedmont, 이탈리아, 10126
- 모병
- A.O.U. Citta della Salute e della Scienza di Torino
-
연락하다:
- Giuditta Cuccuru
- 전화번호: +39 011 6335351
- 이메일: gcuccuru@cittadellasalute.to.it
-
수석 연구원:
- Antonino Loforte, MD
-
-
-
-
CBohmia
-
Prague, CBohmia, 체코, 14021
- 모병
- IKEM Prague
-
수석 연구원:
- Ivan Netuka, MD
-
연락하다:
- 전화번호: +42 060 665 4220
- 이메일: martina.kucerova@ikem.cz
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subject has provided written informed consent by signing the study Informed Consent Form (ICF) prior to any clinical investigation-related procedure
- LVEF ≤30% and Cardiac Index ≤ 2.5 L/min/m²
- Limited functional status as demonstrated by 6MWT ≤ 350 m due to HF related reasons OR peak VO2 ≤ 14 mL/kg/min (or <50% of predicted peak VO2 value)
- NYHA Class IIIB or NYHA Class IV
- Subject has ≥ 1 Heart Failure Hospitalization in the last 12 months
- Subject is already implanted with a CardioMEMS PA Sensor OR willing to undergo a CardioMEMS PA Sensor implant
- Subject is willing and able to be implanted with the HM3 LVAS if randomized to HM3 Group
Randomization Criteria:
- Subject has been implanted with a CardioMEMS PA Sensor for at least 90 days.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP ≥ 30 mmHg.
- The subject will not be randomized if they have any other factor that represents inordinate risk for either continued GDMT or LVAD implant.
Single Arm Registry Criteria:
- Subject has received a CardioMEMS PA Sensor implant following enrollment in the trial.
- Subject is receiving guideline directed medical therapy with optimal doses (or documented medication contraindication or intolerance) of betablockers, Angiotensin-Converting-Enzyme-inhibitors or Angiotensin II Receptor Blockers or angiotensin receptor neprilysin inhibitor (if eligible), Mineralocorticoid Receptor Antagonists, Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors, and diuretics for at least 30 of the last 90 days.
- mean PAP <30 mmHg
Exclusion Criteria:
-
Subject is < 18 years of age at the time of informed consent.
-
Dependent on IV inotrope in the last 30 days.
-
Contra-indications to HM3 LVAS or CardioMEMS HF system.
-
Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy.
-
Technical obstacles to LVAD or CardioMEMS implantation which pose an inordinately high surgical risk, in the judgment of the implanter.
-
Existence of ongoing MCS.
-
Presence of mechanical aortic valve that will not be either converted to a bioprosthesis or oversewn at the time of LVAD implant.
-
History of any solid organ transplant.
-
Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management.
-
Presence of an active, uncontrolled infection.
-
Complex congenital heart disease.
-
Currently Pregnant or capable of becoming Pregnant and Unwilling to Use Contraception with LVAD.
-
History of pulmonary embolism within 30 days prior to enrollment or history of recurrent (>1 episode) pulmonary embolism and/or deep vein thrombosis.
-
Planned VAD or Bi-VAD support prior to enrollment.
-
Presence of any one of the following risk factors for or indications of severe end organ dysfunction or failure:
- An INR ≥ 2.0 not due to anticoagulation therapy
- An eGFR < 30 mL/min/1.73 m2 and nonresponsive to diuretic therapy or receiving chronic dialysis.
- Biopsy proven liver cirrhosis.
- Need for chronic renal replacement therapy.
- History of severe chronic obstructive pulmonary disease (COPD) defined by Forced Expiratory Volume FEV1 < 30% predicted.
- History of cerebrovascular disease with significant (> 80%) uncorrected internal carotid stenosis.
- Significant peripheral vascular disease (PVD) accompanied by ischemic rest pain or extremity ulceration.
-
Any condition other than HF that could limit survival to less than 24 months.
-
Participation in any other clinical investigation with an active treatment arm that is likely to confound study results or affect the study outcome.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Randomized Arm - HM3 Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the HM3 group will receive the device within 14 days of randomization. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
다른 이름들:
The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
다른 이름들:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
다른 이름들:
|
|
실험적: Randomized Arm - Control Group
Patients with elevated mean PAP (mean PAP ≥ 30 mmHg) and randomized to the control group will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
다른 이름들:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
다른 이름들:
|
|
실험적: Single Arm Registry
Patients who do not meet the mean PAP threshold (mean PAP <30 mmHg) and are enrolled in the single arm will continue their medical therapy per established heart failure guidelines. |
The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
다른 이름들:
Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes
기간: 2 years
|
The powered primary endpoint will be analyzed at 2 years following the Com-Nougue method and will be compared between the HM3 Group (HM3 LVAD) and the Control Group (GDMT) within the Intention-to-treat (ITT) population. |
2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate of Safety Outcomes at 1-year
기간: 1 year
|
The powered secondary endpoint of Rate of Safety Outcomes at 1-year will be evaluated within the Intention-to-treat (ITT) population against a pre-specified performance goal. Components consist of the following:
|
1 year
|
|
Survival at 2 years
기간: 2 years
|
The powered secondary endpoint of survival at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. |
2 years
|
|
Quality of life score assessed with the Kansas City Cardiomyopathy Questionnaire
기간: 2 years
|
The secondary endpoint of Quality-of-life score at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Quality of life at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. The KCCQ scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Improvement of KCCQ by at least 10 points is considered clinically significant. |
2 years
|
|
Six-minute walk distance
기간: 2 years
|
The secondary endpoint of six-minute walk distance at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of six-minute walk distance at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Hospitalizations for HF and/or Urgent HF Visit
기간: 2 years
|
The secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of Hospitalizations for HF and/or Urgent HF Visit at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
Days alive and outside of the hospital
기간: 2 years
|
The secondary endpoint of days alive and outside of the hospital at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of days alive and outside of the hospital at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All-cause hospitalizations
기간: 2 years
|
The secondary endpoint of all-cause hospitalizations at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all-cause hospitalizations at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
|
All adverse events (including all strokes) regardless of severity
기간: 2 years
|
The secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be compared between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the secondary endpoint of all adverse events (including all strokes) regardless of severity at 2-years will be descriptively compared between the Single Arm Registry and both the HM3 Group and Control Group of the Randomized Arm separately. |
2 years
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Finkelstein-Schoenfeld Win Ratio
기간: 5 years
|
The Finkelstein-Schoenfeld Win Ratio will be explored at 5 years as an additional analysis with the following hierarchy:
The Finkelstein-Schoenfeld Win Ratio will be analyzed between the HM3 Group and the Control Group within the Intention-to-treat (ITT) population. Additionally, the Finkelstein-Schoenfeld Win Ratio will be descriptively analyzed between the Single Arm and both the HM3 Group and Control Group of the Randomized Arm separately. |
5 years
|
|
Survival free of urgent LVAD or transplant
기간: 5 years
|
This additional descriptive analysis at 5-years will be performed to evaluate the proportion of patients who are alive and free of device replacement or transplant in the HM3 Group compared to the Single Arm Registry (de novo implant or transplant) |
5 years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Kelly O'Connell, PhD, Abbott
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- ABT- CIP-10521
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .